KW 2478

Drug Profile

KW 2478

Alternative Names: KW-2478

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Kyowa Hakko
  • Developer Kyowa Hakko Kirin
  • Class Antineoplastics; Morpholines
  • Mechanism of Action HSP90 heat-shock protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Haematological malignancies; Multiple myeloma

Most Recent Events

  • 27 Apr 2011 Phase-I/II clinical trials in Multiple myeloma (Combination therapy, Second-line or greater therapy) in Philippines (IV) (NCT01063907)
  • 31 Jan 2011 Kyowa Hakko Kirin completes a phase I trial in Haematological malignancies in the United Kingdom (NCT00457782)
  • 01 Oct 2008 Kirin Pharma Company has merged with Kyowa Hakko to form Kyowa Hakko Kirin
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top